Can MRI predict Crohn's relapse after stopping biologics?
Part of Digestive system clinical trials.
This study looks at whether MRI scans can predict when Crohn's disease will come back after stopping biologic medications. If you are in remission and recently stopped a biologic, researchers want to see if your MRI results can help understand your risk of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 16 or older.
- You have Crohn's disease that affects the small bowel or colon.
- Your Crohn's is currently in remission (you feel well with no active symptoms).
- You recently stopped biologic therapy (like adalimumab, infliximab, or similar) because of remission.
- You had a special MRI scan (MRE) of your small bowel around the time you stopped the biologic.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a shorter, quicker MRE (magnetic resonance imaging of the small bowel) for people with Crohn's disease. It aims to see if the abbreviated scan still provides good images for monitoring inflammation, narrowing, or fistulas.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
This trial compares two types of scans—MRI and ultrasound—to see how well they detect changes in Crohn's disease after treatment. If you've had one of these scans already and need another to check your response to therapy, you may be able to join.
This study looks at how Crohn’s disease healing shows up on a special MRI (MRE) and tries to better define what “healed” means. It may help your care team track healing more accurately, especially inside the bowel.
This study checks whether adding an extra, cross-body “transmural” evaluation (looking at inflammation throughout the bowel) improves care for adults with Crohn’s who are starting or receiving biologic (biotherapy) treatment. It uses close follow-up with stool calprotectin (a marker of gut inflammation) to see if this approach helps control inflammation.
This study uses brain MRI and psychological questionnaires alongside standard Crohn's tests to see if certain brain patterns predict how the disease will progress over six months or more.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.